As previously reported, MM plasma cells are protected in the vascular niche and in advanced phases of the disease, the same stromal cells acquire resistance to anti-myeloma drugs as demonstrated by the nuclear stabilization of HIF-1α in the BM endothelial cells of relapsed/refractory MM patients [51]. The gene discussed is HIF1A; the disease is Miyoshi myopathy.